Safety and Pharmacokinetics of Multiple Doses of Aclidinium Bromide, a Novel Long-Acting Muscarinic Antagonist for the Treatment of Chronic Obstructive Pulmonary Disease, in Healthy Participants

Journal of Clinical Pharmacology

Volumn 49, Issue 10, 2009, Pages 1239-1246

  Jansat, Josep M ^a   Lamarca, Rosa ^a   De Miquel, Gonzalo ^a   Schrödter, Andreas ^b   Miletzki, Barbara ^c   Gurniak, Matthias ^b  

^a Laboratorios Almirall ^*  (Spain)

^b FOCUS Clinical Drug Development GmbH   (Germany)

^c CenTrial GmbH   (Germany)

Author keywords

Aclidinium bromide; Anticholinergic; COPD; Multidose; Pharmacokinetics

Indexed keywords

ACLIDINIUM BROMIDE; DRUG METABOLITE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; DYSPHAGIA; ELECTROCARDIOGRAM; FEMALE; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; MULTIPLE DRUG DOSE; NORMAL HUMAN; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; VITAL SIGN;

ADMINISTRATION, INHALATION; ADULT; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TROPANES;

EID: 70349513461     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009336353     Document Type: Article

References (25)

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001 ; 163: 1256-1276.
2. Barnes PJ The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med. 2004 ; 117 (suppl 12A). 24S - 32S.
3. Agusti AG COPD, a multicomponent disease: implications for management. Respir Med. 2005 ; 99: 670-682.
4. Belmonte KE Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005 ; 2: 297-304.
5. Caulfield MP, Birdsall NJM. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998 ; 50: 279-290.
6. Roffel AF, Alzinga CR, Zaagsma J. M3 receptors mediate contraction of human central and peripheral airway smooth muscle. Pulm Pharmacol. 1990 ; 3: 47-51.
7. Gross NJ, Co E., Skorodin MS Cholinergic bronchomotor tone in COPD: estimates of its amount in comparison with that in normal subjects. Chest. 1989 ; 96: 984-987.
8. Rabe KF, Hurd S., Anzueto A., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007 ; 176: 532-555.
9. Gavalda A., Miralpeix M., Ramos I., et al. Aclidinium bromide, a novel muscarinic receptor combining long residence at M3 receptors and rapid plasma clearance. Eur Respir J. 2007 ; 30 (suppl 51). 209S - 210S.
10. Gavalda A., Sentellas S., Alberti J., et al. Rapid plasma hydrolysis of aclidinium bromide, a novel long-acting anticholinergic drug. Eur Respir J. 2008 ; 32: 638s.
11. Joos GF, Schelfhout VJ, Kanniess F., Ludwig-Sengpiel A., Garcia Gil E., Massana Montejo E. Bronchodilatory effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a phase IIa study. Eur Respir J. 2007 ; 30: 210S.
12. Jansat JM, Lamarca R., Garcia Gil E., Ferrer P. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther. In press.
13. Cortijo J., Sarria B., Gavalda A., Miralpeix M., Morcillo E. In vitro characterization of aclidinium bromide, a novel long-acting anticholinergic: effects on isolated human bronchi. Am J Respir Crit Care Med. 2008 ; 177: A654.
14. Oba Y., Zaza T., Thameem DM Safety, tolerability and risk benefit analysis of tiotropium in COPD. Int J COPD. 2008 ; 3: 1-10.
15. Singh S., Loke YK, Furberg CD Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008 ; 300: 1439-1450.
16. Tashkin DP, Celli B., Senn S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008 ; 359: 1543-1554.
17. Gras J., Gavalda A., Llenas J. The preclinical cardiovascular safety profile of aclidinium bromide, a novel long-acting anticholinergic drug. Am J Respir Crit Care Med. 2008 ; 177: A654.
18. Lasseter KC, Aubets J., Gil EG Aclidinium bromide, a novel long-acting anticholinergic, does not affect QT interval in healthy subjects. Am J Respir Crit Care Med. 2008 ; 177: A655.
19. Cazzola M., Matera MG Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol. 2008 ; 155: 291-299.
20. Nichols J. Combination inhaled bronchodilator therapy in the management of chronic obstructive pulmonary disease. Pharmacotherapy. 2007 ; 27: 447-454.
21. Cazzola M., Centanni S., Santus P., et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med. 2004 ; 98: 1214-1221.
22. Cazzola M., Di Marco F., Santus P., et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther. 2004 ; 17: 35-39.
23. Tashkin DP, Littner M., Andrews CP, Tomlinson L., Rinehart M., Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med. 2008 ; 102: 479-487.
24. van Noord JA, Aumann JL, Janssens E., et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005 ; 26: 214-222.
25. Aaron SD, Vandemheen KL, Fergusson D., et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007 ; 146: 545-555.